cyclic heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-15. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Efforts toward reconstruction in the secessionist South had begun as early as 1862, but it was only after President Lincoln's assassination that the three Reconstruction Amendments to the Constitution were ratified to protect civil rights. The amendments codified nationally the abolition of slavery and involuntary servitude except as punishment for crimes, promised equal protection under the law for all persons, and prohibited denial or abridgment of voting rights on the basis of race, color, or previous enslavement. As a result, African Americans took an active political role in ex-Confederate states in the decade following the Civil War. The former Confederate states were readmitted to the Union, beginning with Tennessee in 1866 and ending with Georgia in 1870. National infrastructure, including transcontinental telegraph and railroads, spurred growth in the American frontier. This was accelerated by the Homestead Acts, through which nearly 10 percent of the total land area of the United States was given away free to some 1.6 million homesteaders. From 1865 through 1917, an unprecedented stream of immigrants arrived in the United States, including 24.4 million from Europe. Most came through the Port of New York, as New York City and other major cities on the East Coast became home to large Jewish, Irish, and Italian populations. Many Northern Europeans as well as significant numbers of Germans and other Central Europeans moved to the Midwest. At the same time, about one million French Canadians migrated from Quebec to New England.
=== 2020s === During the COVID-19 pandemic, the company was one of the major developers and processors of COVID-19 testing. In March 2020, Labcorp received emergency use authorization from the FDA for a test for SARS-CoV-2. In April 2020, the company developed the first COVID-19 test in which people were able to collect a sample at home. In July 2020, the company was processing 165,000 COVID-19 tests per day. In December 2021, the company acquired Toxikon, a contract research organization developing non-clinical testing services. In February 2022, the company acquired Personal Genome Diagnostics and its liquid biopsy and tissue-based genomic product, for $450 million in cash plus a possible earn-out of an additional $125 million. Also in February 2022, Labcorp entered into agreements with Ascension, one of the nation’s largest Catholic and nonprofit health systems, to manage Ascension's hospital-based laboratories in ten states and purchase assets of the health system's outreach laboratory business. In June 2023, Labcorp completed the corporate spin-off of Fortrea. In August 2024, Labcorp acquired the assets of bankrupt Invitae for $234 million. In December 2025, Labcorp acquired the ambulatory lab businesses from Community Health Services (CHS) in 13 states for $194 million. In January 2026, it was announced that Labcorp had sold select assets of its early development medical device testing business to NAMSA, a medical device testing, clinical research, and regulatory consulting company.
=== Pharmacokinetics === Pindolol is rapidly and well-absorbed from the gastrointestinal tract. It undergoes some first-pass metabolism leading to an oral bioavailability of 50 to 95%. Patients with uremia may have a reduced bioavailability. Food does not alter the bioavailability, but may increase the resorption. Following an oral single dose of 20 mg peak plasma concentrations are reached within 1 to 2 hours. The effect of pindolol on pulse rate (lowering) is evident after 3 hours. The drug's volume of distribution is 1.2 to 2 L/kg. The plasma protein binding is 40 to 60%. It crosses the blood–brain barrier and can produce centrally mediated side effects. Despite being moderately lipophilic, pindolol showed greater electroencephalogram (EEG) changes than the highly lipophilic propranolol. As a result, lipophilicity does not appear to be the sole determinant of blood–brain barrier permeability of beta blockers. Approximately two-thirds of pindolol is metabolized in the liver giving hydroxylates, which are found in the urine as gluconurides and ethereal sulfates. The remaining one-third of pindolol is excreted in urine in unchanged form. Despite the rather short elimination half-life of 3 to 4 hours, hemodynamic effects persist for 24 hours after administration. The half-life is increased to 3 to 11.5 hours in patients with renal impairment, to 7 to 15 hours in elderly patients, and from 2.5 to 30 hours in patients with liver cirrhosis.
Sources: en.wikipedia.org
Earthworms use, in addition to the digestive proteins, a class of surface active compounds called drilodefensins, which help digest plant material by counteracting the inhibitory effects of polyphenols on earthworm gut enzymes. Instead of being coiled like a mammalian intestine, in the earthworm's intestine a large mid-dorsal, tongue-like fold is present, called a typhlosole, with many folds running along its length, increasing its surface area to increase nutrient absorption. The intestine has its own pair of muscle layers like the body, but in reverse order: an inner circular layer within an outer longitudinal layer.
Despite these obstacles to their synthesis, a 2013 study published by a group of Russian physicists led by Valeriy Zagrebaev proposes that the longest-lived copernicium isotopes may occur at an abundance of 10−12 relative to lead, whereby they may be detectable in cosmic rays. Similarly, in a 2013 experiment, a group of Russian physicists led by Aleksandr Bagulya reported the possible observation of three cosmogenic superheavy nuclei in olivine crystals in meteorites. The atomic number of these nuclei was estimated to be between 105 and 130, with one nucleus likely constrained between 113 and 129, and their lifetimes were estimated to be at least 3,000 years. Although this observation has yet to be confirmed in independent studies, it strongly suggests the existence of the island of stability, and is consistent with theoretical calculations of half-lives of these nuclides. The decay of heavy, long-lived elements in the island of stability is a proposed explanation for the unusual presence of the short-lived radioactive isotopes observed in Przybylski's Star.
Vitamin D needs can be met via the human body's own generation upon sufficient and sensible exposure to ultraviolet (UV) light in sunlight. Products including milk, soy milk and cereal grains may be fortified to provide a source of vitamin D. For those who do not get adequate sun exposure or food sources, vitamin D supplementation may be necessary.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.